4 top lessons the Theranos scandal can teach us as investors 

The Theranos story presents a timely reminder of some age-old investment wisdom that can help me avoid some basic stock-picking pitfalls.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I, like many of you, will be watching the gripping miniseries, The Dropout. It unpacks one of the most bizarre cases of corporate fraud you will ever see. By a blood-testing start-up called Theranos, no less.

The company managed to dupe many high-profile investors. It shows me that I am never too old to learn an investment lesson.

Putting the Theranos case study into context

So, in 2014 Elizabeth Holmes was a 30-year-old billionaire. She had founded a company valued at $9bn (£6.5bn) for supposedly bringing about a revolution in diagnosing disease.

The only problem? The technology didn’t work.

Soon enough, Holmes was exposed as a fake. In honour of the high-profile debacle, here are five lessons from the Theranos story that continue to serve me well in my investment journey. 

Always evaluate the track record of the management team

Firstly, a big clue is in the title of the miniseries – The Dropout. The fact the CEO of the start-up was a university dropout with no track record in the medical industry is an immediate red flag for me.

The saying goes, “there are no bad companies, only bad managers.” To invest, I must believe beyond doubt that the management team are competent and know what they are doing. Otherwise, I don’t!

Don’t worry about other people

As with many trends in life, herd theory occurs in finance when investors follow the crowd instead of their own analysis. In the case of Theranos, the crowd included bigwigs like Larry Ellison and Henry Kissinger. But, no matter how clever I believe my potential co-investors are, it will never be enough to convince me to invest in a stock. At least not unless I have justified this with my own view.

I never invest in businesses that I do not understand

At one point Theranos claimed to be able to perform all manner of tests, ranging from cholesterol levels to complex genetic analysis. All with just a single pinprick of blood.

Admittedly, I am no geneticist, and haven’t met many. This, in all likelihood, means that I will not understand complex genetic analysis. That is my personal signal to avoid investment.

If I don’t understand a stock, I do not invest in it.

I avoid concentration risk at all costs

Concentration risk occurs when I rely too much on a single investment; for example, a single company’s shares.

So, my prime objective is to avoid an over-reliance on a particular stock or security. My portfolio could be exposed to severe losses if the company goes bust. This turned out to be the reality for many an investor in Theranos.

As such, I counter this by spreading my investment risk by diversifying across sectors, asset classes and regions.

I will never invest in a business I do not understand

In conclusion, investment sage Warren Buffett once said “never invest in a business you cannot understand”. This is the rule I have found to be the most important in my stock-picking journey.

As an investor, independent thought and analysis has served me well.

In the end, I’d rather blame myself for my investment mistake, than someone like Elizabeth Holmes.

Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Night Takeoff Of The American Space Shuttle
Growth Shares

How UK investors can get access to the $2trn SpaceX stock IPO TODAY

Investors in the UK can get exposure to space powerhouse SpaceX today via several investment trusts that trade on the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Down 23% from its highs, I’ve just bagged myself a FTSE 100 bargain!

Stephen Wright has seized the opportunity to buy shares in a FTSE 100 company with outstanding growth prospects at an…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

How to turn an empty ISA into £100 a month in passive income

Stephen Wright outlines how real estate investment trusts can help UK investors aim for £100 a month in passive income…

Read more »

Man riding the bus alone
Investing Articles

Down 23%! Should I buy Meta Platforms for my ISA or SIPP?

Meta stock looks undervalued after sliding steadily lower since last summer. But should I buy the social media giant for…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£5,000 invested in Greggs shares 2 years ago is now worth…

Anyone who bought Greggs' shares two years ago will now be sitting on heavy losses. Is there potential for a…

Read more »

Investing Articles

10 days to the next stock market crash?

What happens to the stock market when the current ceasefire in the Middle East expires? And what should investors do…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

How to try and double the State Pension with just £30 a week

By saving money each week and investing regularly, even someone without a lot of cash to spare can aim to…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

2 badly beaten-down small caps to consider for a £20,000 Stocks and Shares ISA

Ben McPoland highlights a pair of UK small caps that have sold off heavily, making them worth considering for a…

Read more »